Earnings Feed
Start Free
Home/Filings/4/0001735276-26-000012
4//SEC Filing

Tanguler Tolga 4

Accession 0001735276-26-000012

CIK 0001178670other
View on SEC.govCompany Profile

Filed

Jan 13, 7:00 PM ET

Accepted

Jan 14, 4:22 PM ET

Size

42.9 KB

Accession

0001735276-26-000012

Insider Transaction Report

Form 4
Period: 2026-01-11
ALNYLAM PHARMACEUTICALS, INC.ALNY
Tanguler Tolga
EVP, Chief Commercial Officer
Transactions
  • Award

    Common Stock

    [F1]
    2026-01-11+3,800→ 31,238 total
  • Sale

    Common Stock

    [F2][F3]
    2026-01-12$353.95/sh−39$13,804→ 31,199 total
  • Sale

    Common Stock

    [F2][F4]
    2026-01-12$355.16/sh−42$14,917→ 31,157 total
  • Sale

    Common Stock

    [F2][F5]
    2026-01-12$356.09/sh−41$14,600→ 31,116 total
  • Sale

    Common Stock

    [F2][F6]
    2026-01-12$357.17/sh−96$34,288→ 31,020 total
  • Sale

    Common Stock

    [F2][F7]
    2026-01-12$358.18/sh−123$44,056→ 30,897 total
  • Sale

    Common Stock

    [F2][F8]
    2026-01-12$359.14/sh−85$30,527→ 30,812 total
  • Sale

    Common Stock

    [F2][F9]
    2026-01-12$360.22/sh−155$55,834→ 30,657 total
  • Sale

    Common Stock

    [F2][F10]
    2026-01-12$361.45/sh−98$35,422→ 30,559 total
  • Sale

    Common Stock

    [F2][F11]
    2026-01-12$362.38/sh−73$26,454→ 30,486 total
  • Sale

    Common Stock

    [F2][F12]
    2026-01-12$363.55/sh−47$17,087→ 30,439 total
  • Sale

    Common Stock

    [F2][F13]
    2026-01-12$364.83/sh−199$72,601→ 30,240 total
  • Sale

    Common Stock

    [F2][F14]
    2026-01-12$365.56/sh−220$80,423→ 30,020 total
  • Sale

    Common Stock

    [F2][F15]
    2026-01-12$366.41/sh−50$18,321→ 29,970 total
  • Sale

    Common Stock

    [F2][F16]
    2026-01-12$367.40/sh−41$15,063→ 29,929 total
  • Sale

    Common Stock

    [F2][F17]
    2026-01-12$368.62/sh−92$33,913→ 29,837 total
  • Sale

    Common Stock

    [F2][F18]
    2026-01-12$369.48/sh−40$14,779→ 29,797 total
  • Sale

    Common Stock

    [F2][F19]
    2026-01-12$370.87/sh−19$7,047→ 29,778 total
  • Sale

    Common Stock

    [F2][F20]
    2026-01-12$372.46/sh−2$745→ 29,776 total
  • Sale

    Common Stock

    [F2][F21]
    2026-01-12$374.44/sh−14$5,242→ 29,762 total
  • Sale

    Common Stock

    [F2]
    2026-01-12$375.65/sh−19$7,137→ 29,743 total
  • Sale

    Common Stock

    [F2]
    2026-01-12$377.82/sh−15$5,667→ 29,728 total
Footnotes (21)
  • [F1]On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026.
  • [F10]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F11]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F12]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F13]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F14]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $365.01 to $366.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F15]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $366.03 to $366.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F16]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $367.04 to $368.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F17]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $368.09 to $369.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F18]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $369.13 to $369.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F19]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $370.43 to $371.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F2]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations.
  • [F20]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $372.35 to $372.50. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F21]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $374.08 to $374.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F5]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F6]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F7]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F8]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  • [F9]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Signature
By: Brett Budzinski, Attorney-in-Fact For: Tolga Tanguler|2026-01-14

Documents

1 file

Issuer

ALNYLAM PHARMACEUTICALS, INC.

CIK 0001178670

→
Entity typeother

Related Parties

1
  • filerCIK 0001849458

Filing Metadata

Form type
4
Filed
Jan 13, 7:00 PM ET
Accepted
Jan 14, 4:22 PM ET
Size
42.9 KB
View on SEC.gov